GlassScriptPhysician profile
Theresa M Redling
NPI 1295840379
$7,216.33
in general payments reported to CMS, 2019-2025
42 companies · $790 in 2025
The $790 reported for 2025 was more than what 86% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $333 · 2021: $570 · 2022: $352 · 2023: $607 · 2024: $3,792 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,289 · Consulting Fee: $2,055 · Travel and Lodging: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,289.24 |
| Consulting Fee | $2,055.00 |
| Travel and Lodging | $845.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,200.46 | 2019-2024 | Eliquis |
| Pfizer INC. | $370.08 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $306.95 | 2019-2022 | |
| Lilly USA, LLC | $302.00 | 2019-2025 | Kisunla, Amyvid |
| Eisai INC. | $291.60 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $264.00 | 2023-2025 | Gemtesa |
| Ge Healthcare | $237.49 | 2020-2025 | |
| Mylan Specialty L.P. | $235.58 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $208.66 | 2019-2025 | Capvaxive, Dificid |
| Otsuka America Pharmaceutical, INC. | $169.92 | 2023-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $135.90 | 2019-2022 | |
| Viatris Specialty LLC | $129.71 | 2025 | Yupelri |
| Abbvie INC. | $113.09 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $110.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $108.08 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theresa Redling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.